

 Early Warning System

EIB-20240568

ALFASIGMA INNOVATIVE DRUGS RDI II



Quick Facts

Countries	Italy
Financial Institutions	European Investment Bank (EIB)
Status	Approved
Bank Risk Rating	U
Voting Date	2025-06-27
Borrower	ALFASIGMA SPA
Sectors	Industry and Trade
Investment Type(s)	Loan
Investment Amount (USD)	\$ 175.81 million
Project Cost (USD)	\$ 718.47 million



Project Description

According to the Bank's website, the project will finance the Promoter's research, development and innovation (RDI) activities 2025-2027 targeting innovative medicines focused on gastroenterology, immune-mediated conditions and rare diseases.

The Project focuses on the research, development and commercialisation of medicinal products to improve the survival and quality of life of patients, by an established European Company.

The aim is to support RDI in developing medicinal products to address unmet medical needs, promoting activities that generate significant positive impacts on knowledge, technology, and the environment. This is achieved through creating innovative processes and products, as well as enhancing skills development and upgrading.



Early Warning System Project Analysis

According to the Environmental and Social Data Sheet, the Project concerns investments in research and development for which no significant impact on the environment is expected.



Investment Description

- European Investment Bank (EIB)



Private Actors Description

According to the Company's website, *Alfasigma* is a global pharmaceutical company founded over 75 years ago in Italy, where it is headquartered (in Bologna and Milan). The Group operates in over 100 markets spanning Europe, North and South America, Asia, and Africa. Alfasigma employs approximately 4,000 people dedicated to research, development, production, and distribution of medicinal products. It focuses on three main therapeutic areas: Gastroenterology, Vascular, and Rheumatology. Its portfolio spans from primary care to specialty care, rare disease medications, and consumer health products, including medical foods and nutraceuticals.



Private Actor 1	Private Actor 1 Role	Private Actor 1 Sector	Relation	Private Actor 2	Private Actor 2 Role	Private Actor 2 Sector
-	-	-	-	Alfasigma S.p.A.	Client	-



Contact Information

No contacts available at the time of disclosure.

ACCESS TO INFORMATION

You can submit an information request for project information at: <https://www.eib.org/en/infocentre/registers/request-form/request-form-default.htm>

ACCOUNTABILITY MECHANISM OF EIB

The EIB Complaints Mechanism is designed to facilitate and handle complaints against the EIB by individuals, organizations or corporations affected by EIB activities. When exercising the right to lodge a complaint against the EIB, any member of the public has access to a two-tier procedure, one internal - the Complaints Mechanism Office - and one external - the European Ombudsman. A complaint can be lodged via a written communication addressed to the Secretary General of the EIB, via email to the dedicated email address: complaints@eib.org, by completing the online complaint form available at the following address: <http://www.eib.org/complaints/form> via fax or delivered directly to the EIB Complaints Mechanism Division, any EIB local representation office or any EIB staff. For further details, check: http://www.eib.org/attachments/strategies/complaints_mechanism_policy_en.pdf

When dissatisfied with a complaint to the EIB Complaints Mechanism, citizens can then turn towards the European Ombudsman. A memorandum of Understanding has been signed between the EIB and the European Ombudsman establishes that citizens (even outside of the EU if the Ombudsman finds their complaint justified) can turn towards the Ombudsman on issues related to 'maladministration' by the EIB. Note that before going to the Ombudsman, an attempt must be made to resolve the case by contacting the EIB. In addition, the complaint must be made within two years of the date when the facts on which your complaint is based became known to you. You can write to the Ombudsman in any of the languages of the European Union. Additional details, including filing requirements and complaint forms, are available at: <http://www.ombudsman.europa.eu/atyourservice/interactiveguide.faces>



Bank Documents

- [Environmental and Social Data Sheet \(ESDS\) - ALFASIGMA INNOVATIVE DRUGS RDI II](#)